Core Viewpoint - China Biotechnology Services (08037) announced a loan agreement to support the construction of a boron neutron capture therapy center, aiming to provide cancer treatment services by the end of 2025 [1] Group 1: Loan Agreement - The company’s indirect wholly-owned subsidiary, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., entered into a loan contract with Hainan Rural Commercial Bank, with a maximum principal amount of RMB 180 million [1] - The loan will facilitate the establishment of the boron neutron capture therapy center [1] Group 2: Future Plans - The center is expected to open and commence operations by the end of 2025, targeting cancer patients in need of boron neutron therapy services [1] - The company aims to develop a network of boron neutron capture therapy centers across China, leveraging the supportive policies of the Boao Lecheng Pilot Zone and establishing franchised hospitals to generate additional revenue [1]

Core Viewpoint - China Biotechnology Services (08037) has announced a loan agreement to support the construction of a boron neutron capture therapy center, aiming to provide cancer treatment services by the end of 2025 [1] Group 1: Loan Agreement - The company has entered into a loan contract with Hainan Rural Commercial Bank, with a maximum principal amount of RMB 180 million [1] - The loan will assist in the establishment of the boron neutron capture therapy center [1] Group 2: Future Plans - The center is expected to open and commence operations by the end of 2025, targeting cancer patients in need of boron neutron therapy [1] - The company aims to develop a network of boron neutron capture therapy centers across China, leveraging the supportive policies of the Boao Lecheng Pilot Zone [1] - Plans include the development of franchised hospitals to generate additional revenue [1]